Key facts
- Lundbeck's Phase IIb trial for bocunebart met its primary endpoint.
- Bocunebart demonstrated a statistically significant reduction in monthly migraine days versus placebo over 12 weeks.
- The trial included patients with one to four prior preventive treatment failures.
- Data was presented at the American Headache Society congress.
Lundbeck announced positive results from the intravenous portion of its Phase IIb clinical dose-finding trial, PROCEED, for its migraine prevention drug candidate, bocunebart (Lu AG09222). The trial met its primary endpoint, demonstrating a statistically significant reduction in monthly migraine days compared to placebo over a 12-week period. This efficacy was observed in patients who had experienced one to four prior failures with preventive migraine treatments. The findings were presented at the American Headache Society (AHS) congress. Lundbeck plans to advance bocunebart to further clinical development stages.